Immunogenic anti-cancer chemotherapy as an emerging concept

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

2007 • 2,814 citations

Anticancer activities of histone deacetylase inhibitors

2006 • 2,813 citations

Calreticulin exposure dictates the immunogenicity of cancer cell death

2006 • 2,789 citations

IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

2001 • 2,658 citations

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

2007 • 2,297 citations

THE B7 FAMILY REVISITED

2005 • 2,239 citations

HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine

2000 • 1,594 citations

Immunological aspects of cancer chemotherapy

2007 • 1,535 citations

Immune surveillance of tumors

2007 • 1,325 citations

Identification of a factor that links apoptotic cells to phagocytes

2002 • 1,323 citations

TNF/TNFR FAMILY MEMBERS IN COSTIMULATION OF T CELL RESPONSES

2004 • 1,320 citations

Adaptive immunity maintains occult cancer in an equilibrium state

2007 • 1,307 citations

Toll-like receptor 9–dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE

2007 • 1,306 citations

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

2005 • 1,246 citations

PD-1 and PD-1 ligands: from discovery to clinical application

2007 • 1,199 citations

Danger signals: SOS to the immune system

2001 • 1,198 citations

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

2006 • 1,180 citations

Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity

2005 • 1,010 citations

Regulation of Phagosome Maturation by Signals from Toll-Like Receptors

2004 • 982 citations

Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity

2005 • 972 citations

CTLA-4: new insights into its biological function and use in tumor immunotherapy

2002 • 923 citations

High mobility group box 1 protein interacts with multiple Toll-like receptors

2005 • 905 citations

NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous Malignancy

2008 • 777 citations

Toll-Like Receptor 8-Mediated Reversal of CD4 ⁺ Regulatory T Cell Function

2005 • 734 citations

Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function

2005 • 616 citations

Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

2007 • 612 citations

Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy

2006 • 556 citations

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

2007 • 531 citations

B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.

2003 • 481 citations

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells

2004 • 476 citations

Molecular characteristics of immunogenic cancer cell death

2007 • 449 citations

Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development

2002 • 447 citations

Development of TLR9 agonists for cancer therapy

2007 • 409 citations

Epitope Landscape in Breast and Colorectal Cancer

2008 • 408 citations

Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response

2005 • 403 citations

A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer

2007 • 397 citations

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

2008 • 383 citations

Treatment of Vulvar Intraepithelial Neoplasia with Topical Imiquimod

2008 • 372 citations

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

2008 • 368 citations

Nature's TRAIL—On a Path to Cancer Immunotherapy

2003 • 361 citations

Natural Killer Cell–Mediated Lysis of Hepatoma Cells via Specific Induction of NKG2D Ligands by the Histone Deacetylase Inhibitor Sodium Valproate

2005 • 351 citations

The B7 Family and Cancer Therapy: Costimulation and Coinhibition

2007 • 326 citations

The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death

2008 • 319 citations

Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1

2007 • 314 citations

Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)

2007 • 304 citations

Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro

2006 • 292 citations

Review: Anti–CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse Events

2007 • 280 citations

Bystander elimination of antigen loss variants in established tumors

2004 • 259 citations

Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis

2008 • 254 citations

Eradication of established tumors in mice by a combination antibody-based therapy

2006 • 252 citations

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma

2008 • 244 citations

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

2007 • 238 citations

Signaling through OX40 (CD134) breaks peripheral T-cell tolerance

2001 • 235 citations

Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy

2004 • 204 citations

Essential role of CD91 in re-presentation of gp96-chaperoned peptides

2004 • 204 citations

A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model

2007 • 201 citations

Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4

2001 • 200 citations

Cyclophosphamide induces type I interferon and augments the number of CD44hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer

2000 • 196 citations

MFG-E8–mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF

2007 • 194 citations

Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model

2008 • 194 citations

Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer

2005 • 168 citations

An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma

2007 • 160 citations

Cytotoxic T-Lymphocyte–Associated Antigen-4

2011 • 150 citations

4-1BB-Specific Monoclonal Antibody Promotes the Generation of Tumor-Specific Immune Responses by Direct Activation of CD8 T Cells in a CD40-Dependent Manner

2002 • 138 citations

Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma

2006 • 124 citations

Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study

2009 • 122 citations

Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself

2007 • 119 citations

4-1BB and OX40 Dual Costimulation Synergistically Stimulate Primary Specific CD8 T Cells for Robust Effector Function

2004 • 116 citations

Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma

2006 • 112 citations

Inhibitory Effect of Toll-Like Receptor 4 on Fusion between Phagosomes and Endosomes/Lysosomes in Macrophages

2004 • 110 citations

Monoclonal Antibodies in the Treatment of Non-Hodgkin???s Lymphoma

2007 • 110 citations

The promise of 4‐1BB (CD137)‐mediated immunomodulation and the immunotherapy of cancer

2008 • 108 citations

Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma

2007 • 107 citations

OX40 Costimulation Synergizes with GM-CSF Whole-Cell Vaccination to Overcome Established CD8+ T Cell Tolerance to an Endogenous Tumor Antigen

2006 • 105 citations

Anti‐OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer

2008 • 88 citations

Scavenger Receptor-A–Targeted Leukocyte Depletion Inhibits Peritoneal Ovarian Tumor Progression

2007 • 84 citations

Imiquimod as an antiangiogenic agent.

2005 • 81 citations

Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle

2003 • 79 citations

Scavenger Receptor-A Negatively Regulates Antitumor Immunity

2007 • 77 citations

Cleavage of Endoplasmic Reticulum Proteins in Hepatocellular Carcinoma: Detection of Generated Fragments in Patient Sera

2006 • 76 citations

Intrinsic sensor of oncogenic transformation induces a signal for innate immunosurveillance

2008 • 75 citations

Topical Immunomodulation in Dermatology: Potential of Toll-like Receptor Agonists

2004 • 70 citations

Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer

2006 • 67 citations

Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all

2007 • 65 citations

Combined IL-21 and Low-Dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model

2006 • 65 citations

Cytotoxic T-Lymphocyte–Associated Antigen-4

2007 • 60 citations

Dual immunoregulatory pathways of 4-1BB signaling

2006 • 59 citations

Cooperation between CD4 and CD8 T cells for anti‐tumor activity is enhanced by OX40 signals

2007 • 53 citations

Proteomics of acute myeloid leukaemia: cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications

2006 • 52 citations

Eradication of established renal cell carcinoma by a combination of 5‐fluorouracil and anti‐4‐1BB monoclonal antibody in mice

2008 • 42 citations

IFN-γ-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice

2002 • 41 citations

Experimental therapy for colon cancer: Anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53

2007 • 34 citations

HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: Results of a phase 1 and PK study

2006 • 32 citations

The small-molecule immune response modifier imiquimod – its mode of action and clinical use in the treatment of skin cancer

2006 • 31 citations

Immunotherapeutic Strategies for High-Risk Bladder Cancer

2007 • 30 citations

Interleukin 21 Enhances Antibody-Mediated Tumor Rejection

2008 • 28 citations

Topical CpG Enhances the Response of Murine Malignant Melanoma to Dacarbazine

2008 • 26 citations

Treatment of locally metastatic melanoma: a novel approach.

2007 • 20 citations

Tumor chemo-immunotherapy using gemcitabine and a synthetic dsRNA

2008 • 20 citations

Combination of 5-FU and IFNα enhances IFN signaling pathway and caspase-8 activity, resulting in marked apoptosis in hepatoma cell lines

2006 • 19 citations

Influence of Activation State of ErbB-2 (HER-2) on Response to Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil for Stage II, Node-Positive Breast Cancer: Study 8541 From the Cancer and Leukemia Group B

2008 • 10 citations

Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival

2007 • 7 citations

Phase I/II study of GM-CSF gene-transduced allogeneic prostate cancer cellular immunotherapy (GVAX IT) in advanced prostate cancer patients made lymphopenic by chemotherapy and infused with autologous peripheral blood mononuclear cells (MC)

2006 • 2 citations

Combination of bevacizumab (B) plus immunotherapy, with interleukin-2 (IL-2) and interferon-α (IFN-α) plus chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC): Dose-finding phase II trial

2007 • 1 citations